B7-1
| T lymphocyte activation antigen CD80 | ||
|---|---|---|
| other names |
Activation B7-1 antigen, BB1, CTLA-4 counter-receptor B7.1, B7 |
|
| Properties of human protein | ||
| Mass / length primary structure | 288 amino acids , 33,048 Da | |
| Secondary to quaternary structure | Homodimer | |
| Identifier | ||
| External IDs | ||
| Orthologue (human) | ||
| Entrez | 941 | |
| UniProt |
P33681
|
|
| PubMed search |
941
|
|
B7-1 (synonymous lymphocyte activation antigen CD80 ) is a surface protein from the immunoglobulin superfamily and, as a costimulator, is involved in the activation of T cells in the course of the immune response .
properties
B7-1 is produced by activated antigen presenting cells such as macrophages and dendritic cells . It forms homodimers . Activation via a co-stimulator provides the necessary second activation signal for T cells. B7-1 binds - like B7-2 - to CD28 (T cell activating), CTLA-4 (T cell inactivating) or PD-L1 . B7-1 is glycosylated and phosphorylated .
B7-1 is the cellular receptor of the adenoviruses of group B.
Abatacept is a fusion protein of CTLA-4 and an Fc fragment and binds to B7-1. It's being studied to treat rheumatoid arthritis .
Web links
Individual evidence
- ↑ S. Bhatia, M. Edidin, SC Almo, SG Nathenson: B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties. In: Immunology letters. Volume 104, Number 1-2, April 2006, pp. 70-75, doi : 10.1016 / j.imlet.2005.11.019 , PMID 16413062 .
- ^ Charles Janeway: The production of armed effector T cells. In: Immunobiology (2001). February 3, 2017, accessed May 17, 2017 .
- ^ R. Korhonen, E. Moilanen: Abatacept, a novel CD80 / 86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis. In: Basic & clinical pharmacology & toxicology. Volume 104, Number 4, April 2009, pp. 276-284, doi : 10.1111 / j.1742-7843.2009.00375.x , PMID 19228144 .